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Metal–organic frameworks (MOFs) have emerged as one of the most fascinating libraries 
of porous materials with a huge potential in very diverse application areas. In particular, 
the bioanalytical and biomedical fields have evolved tremendously due to the emergence 
of these hybrid inorganic-organic MOF-based materials. This is because these materials 
possess a series of key properties essential for bio-applications, such as minimal toxicity 
to living cells, intrinsic biodegradability, and possibility of synthesizing with nanoscale 
sizes. Additional properties of MOFs such as ultra-large surface-to-volume ratios, tunable 
pore size, high drug loading capacity, tunable structure and chemical composition, and 
potential for multiple post-synthetic modification make them ideal candidates for drug 
delivery. This review highlights recent research progress on MOF-based drug delivery 
systems (DDS), pointing out the evolution of these systems towards the development of 
theranostic nanoplatforms. Rather than a comprehensive review, representative recent 
examples are selected to illustrate such an evolution, and a critical discussion of the 
advantages and limitations of the different DDS types is given. Finally, the remaining 
challenges and future opportunities in this field are presented, highlighting that 
overcoming the current issues will pave the way towards the elusive dream of 
‘personalized medicine’. 
 







The involvement of metal-organic frameworks (MOFs) in a myriad of diverse fields has 
brought forward a true revolution, and it is therefore not by chance that MOF-based 
materials are currently one of the hot topics in the field of hybrid porous solids [1-3]. 
MOFs, also known as porous coordination polymers (PCPs) or coordination networks, 
are a class of hybrid porous materials formed by the self-assembly of polydentate organic 
ligands (carboxylates, imidazolates, or phosphonates) and metal-containing nodes 
(isolated cations, clusters, or chains) linked through coordination bonds, and resulting in 
networks with potential voids [4-7]. The acronym ‘‘MOF” was first introduced by Yaghi 
and co-workers in 1999 [8], and nowadays they are a huge family with about 20,000 
different structures (as reported in Cambridge database [7]) and with quite diverse 
properties. Regardless of the MOF type, all of them present high - porosities (with pore 
diameter up to 9.8 nm; pore volume up to 4.4 cm3·g-1) [7, 9, 10], which is ideal for capture, 
storage, separation, and/or delivery applications. Owing to the modular nature, the 
specific physical and chemical properties (e.g., pore size, hydrophilic or hydrophobic 
nature within the pores or the surface, catalytic sites) of MOF materials can be 
systematically tuned by judicious selection of building blocks [11], and a variety of 
functional moieties can be introduced into metal containing nodes, organic ligands, or 
pore spaces through pre-designing or post-synthetic approaches [12-14]. It is important 
to note that -the synthetic conditions (e.g., counter ions, solvent, pH, metal–ligand ratio, 
temperature and reaction time) also have a strong influence on the structure of the MOFs, 
as well as on their physico-chemical properties [15, 16]. These mutable properties have 
expanded the versatility of these materials, making them attractive alternatives to the 
traditional porous materials [1, 17, 18].  
While the first applications (named as “classical applications”) of MOFs were mainly 
focused on gas adsorption (storage and selective separation) [19-21], catalysis [1, 22, 23], 
and sensing [24], the implementation of MOFs in green applications (e.g., solar energy 
conversion, energy storage, air/water pollution remediation) has aroused much interest 
and a bright future is expected [25, 26]. Analytical chemistry has also benefited from the 
potential of MOFs [27,28], which are involved as sorbent materials in analytical sample 
preparation methods [29-32], as stationary phases in analytical separation techniques [31, 
33, 34], and as sensors in spectroscopy and/or electroanalytical methods [35, 36]. On the 
other hand, the development of synthetic methods for the preparation of MOFs at the 
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nanoscale [13, 37] (i.e., nanoscale MOFs, nanosized MOFs, or nMOFs) was a major 
breakthrough which opened the door to explore their potential in bio-applications. 
Nowadays there are numerous synthetic methods for scaling down the MOFs to 
nanometer sizes [13, 37-40], but all of them can be grouped in two main approaches: (i) 
Confinement of the self-assembly of metal ions and organic linkers to force the MOF 
formation at nanoscopic locations, for example by using emulsions, templates, or 
surfactants; and (ii) favouring the nucleation versus crystal growth, for example by using 
fast precipitation methods, or microwave and ultrasound synthesis. In addition, many 
kinds of nMOFs have showed low cytotoxicity, which guarantees eventual in vivo 
applications, and nMOFs are also intrinsically biodegradable in view of the relatively 
labile metal-ligand bonds [41], making it possible to rapidly degrade and clear away after 
the intended mission is accomplished. These specific features of the nMOFs have enabled 
them as an ideal platform for biomedical applications, such as sensing and imaging for 
diagnostic purposes, and drug delivery for therapeutic applications [40-45]. 
In the field of drug delivery, one of the still remaining challenge is to develop new 
controllable drug delivery systems (DDS) with enhanced therapeutic efficiency by 
overcoming the typical associated drawbacks, i.e. low drug loading, rapid biodegradation, 
instability, low specificity of the treatment, systemic side effects and toxicities. In spite 
of the efforts in exploring different host porous materials for drugs, either organic (such 
as polymeric nanoparticles, liposomes, dendrimers) or inorganic (such as mesoporous 
silica, zeolites), and each of one with its own strengths and drawbacks [46], the ideal 
candidate for their clinical translation has not been found yet [47]. Even if there are 
several systems currently under preclinical development or in clinical trials, and four 
nanosystems already approved by FDA as nanomedicines, i.e. liposomal formulations of 
doxorubicin (Doxil® or Caelex®), daunorubicin (DaunoXome®) and albumin-bound 
paclitaxel (Abraxane®), early clinical data demonstrated that while drug encapsulation 
into these nanocarriers alleviated some dose-limiting toxicities, it did not significantly 
improve treatment efficacy [48, 49].  
To overcome the issue of low efficacy, nMOFs are demonstrating to have a promising 
future thanks to their “hybrid” organic-inorganic nature, bringing the gap of purely 
inorganic and organic nanocarriers. They present the high and well-defined porosity 
typical of inorganic porous materials that is a key feature to achieve a controlled release, 
together with the presence of tunable organic groups within the framework that allows 
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for encapsulating a wide diversity of drugs and large amounts of drug molecules by 
modulating the drug-framework interactions [17, 46]. Significant progress has been 
achieved in the development of MOF-based DDS, but most attempts still remain in the 
proof-of-concept stage. This is because a precise spatio-temporal control and dosage 
control of the drug release under in vitro and in vivo settings, while maintaining minimal 
side effects and biocompatibility, is not an easy task to achieve. The recent advances are 
focused on designing stimuli-responsive MOF-based DDS [50, 51], as well as combining 
therapeutic and diagnostic capabilities (i.e., theranostics) simultaneously within the same 
nMOF [45, 52-54]. 
Several excellent reviews related to the potential of MOFs in drug delivery have been 
published within the period 2017-2018, but each one approached from a different 
perspective [55-59]. Some reviews discuss the bioapplications of MOFs from a broad 
perspective, ranging from the synthetic methods and drug-loading strategies [55-57], to a 
wide variety of applications which cover not only drug delivery but also non-drug 
delivery therapeutics such as photothermal therapy, photodynamic therapy, heavy metal 
adsorption, and antimicrobial activity, among others [58, 59]. On the, Wuttke et al. 
addressed the use of MOFs as drug delivery systems by conducting a comprehensive 
comparison with other nanocarriers such as dendrimers and mesoporous silica 
nanoparticles [60]. In contrast, this review differs in that it will focus on highlighting the 
latest progress in the design of MOFs as DDS and proving a rational classification of the 
MOF-based DDS types depending on the complexity and control level. Rather than 
presenting a comprehensive overview, the aim of this review is to provide a critical 
perspective on the role of MOFs as key players in the context of drug delivery and 
theranostics. For that reason, several key publications within the period 2016-2018 are 
selected to illustrate the progress in MOF-based DDS and to identify the advantages and 
limitations of the different proposed DDS types, with the ultimate goal of motivating 
future research to advance in this field. Thus, it is organized in four sections: first, the key 
properties of MOFs in the context of drug delivery are briefly presented. Second, the 
different types of MOF-based DDS developed so far are classified depending on the 
complexity level, control level, and the stimuli-responsive characteristics, and the 
strengths and weaknesses of each type are pointed out. In a third section, the significance 
of MOFs in the development of promising theranostic nanoplatforms is discussed. 
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Finally, the open issues and challenges for the future perspectives of MOF in the field of 
drug delivery and theranostics are presented. 
This review hopefully can stimulate interdisciplinary research and effective collaboration 
between chemists, pharmacologists and clinicians, since it may be key to converting 
research developed DDS into clinical applications.  
Key features of MOFs for drug delivery 
The vast majority of MOFs possess a number of unique characteristics which are key 
requirements for their potential application as drug delivery systems (DDS), as well as in 
other bio-applications. There are a few strict requirements that one should keep in mind 
when it comes to designing a MOF-based material for its application in drug delivery. 
These key features responsible for its success as DDS are the following: 
i) nanoscale materials; nowadays there are diverse synthetic methods for the preparation 
of MOFs at the nanoscale [13, 37-40], and these nanosized MOFs (below 200 nm) are 
superior as DDS due to their higher cellular uptake (internalization rates), longer blood-
circulation times, and enhanced permeability and retention (EPR) effect to increase the 
drug concentration at tumor regions [43, 52, 61-]. Moreover, the smaller the size (i.e., 
shorter diffusion paths [62, 63]) the faster the delivery kinetics are. 
ii) nontoxic nature; they can be built up from “biologically benevolent” metals and 
organic linkers. The metals more appropriate due to their low toxicity are Fe, Zn, Zr, Mn, 
Mg, and Cu, having oral lethal dose 50 (LD50): 30 g kg–1 for Fe, 350 µg kg–1 for Zn, 4.1 
g kg–1 for Zr, 1.5 g kg–1 for Mn, 8.1 g kg–1 for Mg, and 25 g kg–1 for Cu. As for exogenous 
organic building blocks, terephthalic acid (LD50 = 5 g kg–1), trimesic acid (LD50 = 8.4 g 
kg–1), 1‐methylimidazole (LD50 = 1.13 g kg–1), and 2‐methylimidazole (LD50 = 1.4 g 
kg–1), are generally used [40, 52]. Moreover some MOFs, termed as bioMOFs, can be 
prepared from components that are endogenous and therefore the body can metabolize 
them, reducing side effects [64]. Other type of bioMOF involves the introduction of a 
therapeutic molecule directly as an organic constitutive part of the MOF framework itself 
(i.e., bioactive MOFs) [30]. Even though their individual components are biocompatible 
and endogenous, and the particle size is below 200 nm, sometimes these materials are still 
toxic. This is because parameters like cellular uptake, biodistribution, translocation, and 
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excretion from the body are also highly affected by degradation rate, shape, nature of 
functionalized surface, as well as use of single or repetitive dose, among others [65, 66].  
iii) large pore surfaces and volumes associated with high drug loading capacity; most of 
the nanocarriers show poor drug loading (generally less than 5 wt% of the transported 
drug versus the carrier material), whereas MOFs present much higher loadings. For 
example, the antiviral drug azidothymidine triphosphate (AZT-TP) was loaded in the 
MIL-101-NH2 in an extent as high as 42 wt% [52]. 
iv) high, regular and permanent porosity; the characteristic well-defined porosity of the 
MOFs together with the presence of organic groups within the framework allow a 
controlled and progressive release of the drug avoiding the undesirable “burst effect” (i.e., 
the rapid release of much of the drug) [52, 67]. 
v) chemical and structural tunability; the ability to tune their structures and porosities 
depending on the size, and nature of the drug is a significant advantage of MOFs, which 
allows a better drug interactions and higher loadings [52]. Moreover, some MOFs present 
a high structural flexibility that enables the adaptation of their porosity to the shape of the 
drug/host molecule [68].  
vi) biodegradability; most MOFs display intrinsic biodegradability, at least to some 
degree, upon exposure to aqueous medium because of having relatively labile metal–
ligand bonds in the structure [41], making it possible to rapidly degrade after the intended 
task is completed, and be eliminated from the body preventing endogenous accumulation 
and associated toxicity effects. For example, in the case of MIL-88A a major degradation 
occurs after 7 days at 37 °C of in vitro incubation under physiological conditions. 
Moreover, its degradation products, iron and fumaric acid, are endogenous, and showed 
low toxicity values [52].  
vii) versatility; the amenity of both the inner and outer surfaces of MOFs to 
functionalization (i.e., post-synthetic modification) [69-71] is especially relevant for drug 
delivery. The incorporation of functional groups with different polarity allows to 
modulate the hydrophilic–hydrophobic internal microenvironment, fine-tuning of pore 
size, improving the drug interactions with the framework (e.g., hydrophilic MOF pores 
for drugs with charges opposite to the MOF backbone’s charge), and changing the 
structure of the solid (interconnectivity, pore size, flexibility) to control diffusion through 
the porous structure [72]. Moreover, the incorporation of targeting ligands to bind specific 
receptors and control in vivo fate, as well as functionalization with polymers to improve 
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their in vivo stability or even circumvent the immune system are also commonly used 
strategies [73, 74]. 
Types of MOF-based drug delivery systems 
One of the major challenges of the current nanosystems-based drug delivery that has yet 
to address is how to achieve controlled drug release to the target site without 
compromising the therapeutic efficacy and bioavailability of the drug. In this context, 
MOF-based DDS seems to be a promising approach for addressing this challenge due to 
their unique properties discussed above. 
The past few years have witnessed a substantial rise/increase in the number of nanoscale 
MOFs with specific features and functionalities, and with diverse responsiveness, which 
is greatly contributing to the progress of the drug delivery field for achieving a 
controllable drug release. A rational classification of those MOF-based DDS may help us 
to get a better understanding on the drug release mechanism involved in each case, and 
ultimately improve the design for optimized performance of the DDS. The different 
developed systems developed until now can be classified according to different criteria 
(cf. Fig. 1):  
(i) Depending on the control over its performance. This allows to classify these DDS into 
two main groups: non-controllable DDS, and controllable ones. The non-controllable 
DDS are characterized by their simplicity, but the low control over the dug release limits 
their use to some very specific applications. Note that even if they are termed as non-
controllable systems some control over the release kinetic is possible by modifying the 
nature of the MOF as it will be explained later. In contrast the controllable DDS, known 
as stimuli-responsive MOF-based DDS or on-demand MOF-based DDS, are endowed 
with controlled release functions. The accurate design of a controlled release behavior 
should be based on a full understanding of the relevant stimuli signals and release 
mechanisms. These DDS can provide spatial and temporal control over drug release, at 
least to some degree, as well as dosage control in some cases, and the increase in the level 
of control over the drug release gave rise to different generations of DDS.  
(ii) Depending on the stimulus type. Various stimuli signals, either endogenous (e.g., pH, 
redox activities, biomolecules, etc.), or exogenous (e.g., light, magnetic/electric field, 
temperature, ultrasounds, etc.) can be selected to trigger localized drug release and 
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facilitate its therapeutic action. The selection of one or another will depend mainly on the 
intrinsic properties of the target site (for example the tumor phenotype and anatomical 
location in the case of cancer therapy), as well as on the specific requirements for the 
intended use. Note that most of the endogenous stimuli are chemical-stimuli, whereas the 
exogeneous ones are generally physical-stimuli.  
(iii) Depending on the complexity level. Due to the wide tunability in structural design 
and multifunctionality potential of MOFs, a high level of complexity can be achieved by 
using careful design of the MOF components and further post-synthetic modifications, 
opening up many possibilities in terms of versatility. Exploiting this, MOF-based DDS 
can be designed to respond to a single stimulus or to multiple stimuli. Normally, a higher 
level of complexity implies greater control of the system, although this is not always the 
case. Thus, instead of complicating the DDS unnecessarily, the rule that should be 
followed is: "to be as simple as possible as long as it meets the necessary requirements”. 
 
Fig. 1 Evolution in the development of MOF-based DDS depending on the complexity 
and control level, giving rise to different generations of DDS. 
Non-controllable MOF-based DDS  
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The first type of MOF-based DDS was developed by Férey and co-workers in 2006 [46]; 
they were the first to envisage the potential of MOFs in drug delivery, owing to their 
considerable loading capacities and controlled release behaviour. They synthesized first 
two Cr-based MOFs, named MIL-100(Cr) and MIL-101(Cr) [46], and latter MIL-53(Cr) 
and its much less toxic analogue MIL-53(Fe) [75], exhibiting all of them remarkable 
loading capacities of ibuprofen as model drug (up to an unprecedented 1.4 g of drug per 
gram of porous solid in the case of MIL-101). Studies of the release kinetics in simulated 
body fluid at 37 °C showed that the complete release of ibuprofen from MIL-100(Cr) and 
MIL-101(Cr) occurred after 3 and 6 days, respectively, whereas the complete release from 
MIL-53(Cr) and MIL-53(Fe) took around 21 days. Importantly, these differences 
demonstrated that the release kinetics could be modified considerably by playing with the 
pore size and optimizing the drug-framework interactions. Such possibility of having a 
sustained release during days is owing to the well-defined porosity of the framework, 
which is a clear advantage of MOFs over other traditional nanocarriers. However, other 
MOF-based DDS showed a fast release due to the instability of the MOF under specific 
conditions; this is the case of MIL-100(Fe) and MIL-101(Fe), which disintegrate in 
phosphate solutions because of the strong interactions between phosphates and iron, and 
this degradation was well correlated to drug release [76]. Moreover, nanoscale MOFs are 
more prone to faster degradation because of larger surface areas [77].  
This kind of DDS are known as the first generation of MOF-based DDS, in which the 
system does not respond to any stimulus, and the drug release mechanisms can be merely 
diffusion, ion exchange, or dissolution. Depending on the specific release mechanism, the 
release-profile will be different. For example, there will be a sustained release over a 
period of time in the case that the drug is released by merely diffusion or slow 
degradation, whereas a burst release will be driven by the fast dissolution (i.e., 
dissociation or disintegration) of the MOF under specific medium conditions. In principle 
one could think that a sustained release is desirable as it could lead to a stable blood 
concentration, as well as a minimization of the toxicity effects. Moreover, the slow release 
may protect the drug from degradation processes by increasing its plasmatic half-life and 
bioavailability, and therefore, its efficiency. However, this behaviour is not always the 
desired one. Since the drug efficacy remains the same as long as the drug concentration 
is between the minimum effective level and the maximum safe concentration, maintaining 
the constant drug concentration in the blood is not really required. For some drugs, such 
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as insulin, the constant blood level may not be even desired. In this case insulin has to be 
delivered at the right time, i.e., when the blood glucose level increases, in an accurate 
amount just enough to reduce the glucose level in blood. This clearly points out that the 
desired release profile (i.e., release kinetics) will depend entirely on the intended 
application, and thus the MOF type will have to be chosen accordingly. To avoid the 
premature release issue, that is the leakage of the drug before reaching the target site, 
coatings of silica [78], lipid bilayers [79, 80], and exosomes [81] onto the MOF surface 
were reported to enhance the stability of the nMOF under physiological conditions.  
Single stimulus-responsive MOF-based DDS 
A stimuli-responsive MOFs, also termed as smart MOFs, is defined as a MOF-based 
material, including pristine MOF, MOF composite and their derivative, that can sense a 
stimulus, such as changes in their local environment or exogenous signals, and respond 
in a predictable and controlled manner by altering their inherent physical and/or chemical 
properties. The overall structure may change (dynamic) or remain the same (rigid), and 
the change in the properties of the MOFs can be reversible (if the change is reversed by 
stopping the stimulus or by applying an antagonistic stimulus) or irreversible (if the 
change is permanent and cannot be reversed). The emergence of numerous stimuli-
responsive MOF-based DDS gave rise to the second generation of MOF-based DDS. 
There are two main groups of stimuli: endogenous (e.g., pH, redox activities, 
biomolecules, etc.), or exogenous (e.g., light, magnetic/electric field, temperature, 
ultrasounds, etc.). Every stimulus has advantages and disadvantages, as reflected in the 
selected examples discussed below. Table 1 summarizes the representative examples of 
smart MOF-based DDS commented along the manuscript. 
Endogenous stimuli. These are very suitable when the intrinsic properties of the target 
site are rather different from the surrounding environment. In the case of cancer, the 
tremendous intracellular environment differences between the tumor tissues and the 
normal tissues cause heterogeneities in pH value, redox state, types and amounts of 
biomolecules [82]. These natural gradients make internal stimuli an ideal trigger for 
controlled release and enhanced specificity against tumor cells.  
Among the possible endogenous stimuli, pH is one of the most widely investigated for 
controlled delivery of anticancer drugs because of the acidic tumor extracellular 
microenvironment and intracellular organelles (endosomes and lysosomes). ZIF-8 is a 
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good candidate for the preparation of a pH-responsive DDS due to its pH sensitivity; ZIF-8 is 
stable at pH 7.4 and decomposes under acidic conditions, since the coordination between the 
zinc and imidazolate ions dissociates at pH 5.0–6.0 [83]. As example of these DDS, Zheng et 
al. reported a one‐pot method for the synthesis of nanosized ZIF‐8 to encapsulate the 
anticancer drug doxorubicin (DOX), obtaining a high loading (20 wt%) and an 
homogeneous distribution of the DOX within the mesopores of the ZIF-8 [84]. Results 
demonstrated that these DOX@ZIF-8 nanoparticles could be used as an efficient pH-
responsive DDS, leading to the DOX release in a controlled manner at low pH (5.0–6.5) 
due to the instability of ZIF‐8 under acidic conditions. The good chemical stability of the 
ZIF-8 under physiological conditions (PBS, pH 7.4) is advantageous as it avoids the release 
of the drug in the systemic circulation. Thus, the release only takes place when the system 
reaches selected cells, such as cancer cells, upon activation by the low pH. Alternatively, DDS 
can be designed as a core-shell system being the ZIF-8 a pH-sensitive shell [85-87]. By 
following this approach, poly(acrylic acid)-Zn nanoparticles were used as template and further 
overcoated with a shell of ZIF-8 to give PAA@ZIF-8 nanoparticles [85]. These nanoparticles 
were able to load a quite higher amount of DOX (1.9 g DOX g−1 NPs) than the previous 
DDS example, which may be attributed to electrostatic interactions between the 
negatively charged PAA and positively charged DOX, as well as the coordination 
interaction of Zn(II)‐DOX. Confocal laser scanning microscopy (CLSM) analysis showed 
that DOX was released in a very slow fashion at pH = 7.4, being the cumulative release of 
DOX only about 35 % after 60 h. In contrast, a faster drug release rate was released at pH = 
5.5 (76 % of DOX after 60 h). Studies in breast cancer cell line MCF-7 revealed the pH-
sensitive intracellular behaviour of this DDS, observing that in the absence of DOX loaded the 
cytotoxicity of the PAA@ZIF-8 particles was negligible. More recently, Liang et al. 
synthesized a protein@ZIF-8 as an efficient DDS for DOX using bovine serum albumin 
(BSA) [87]. BSA/DOX nanoparticles were first prepared in one-pot via a desolvation process, 
followed by the growth of a ZIF-8 shell. This porous shell ensures the accessibility of water 
but prevents the leaching of drugs under physiological conditions due to the ultra-small 
window (3.4 Å). Under acidic conditions the ZIF-8 was gradually decomposed leading to the 
release of the DOX, and this DDS presented a much higher efficiency against MCF-7 cells 
than the use of free DOX.  
The significant difference in redox potentials between intracellular and extracellular 
environments is also commonly used as stimulus for DDS. This difference is even more 
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pronounced in tumor tissues.  For example, the concentration of the reducing agent 
glutathione (GSH) within the intracellular cytosol of tumor cells is about 100-fold higher 
than in the extracellular environment [88, 89]. The disulfide bond (SS), a redox‐
responsive group, is stable in mildly oxidative extracellular milieu while it undergoes 
rapid cleavage upon exposure to the high levels of intracellular reducing agents such as 
GSH [90]. Thus, the introduction of disulfide bonds in the construction of the MOF is the 
most straightforward approach for the preparation of GSH-responsive DDS. Lei et al. 
were the first to incorporate organic ligands containing disulfide bonds as linkers within 
the structure of a MOF. Particularly they prepared MOFs using zirconium (Zr) as metal 
centers and 4,4′‐dithiobisbenzoic acid (4,4′‐DTBA) as GSH‐sensitive organic linker 
ligand [91]. This Zr‐DTBA MOF was loaded with the natural polyphenol anticancer drug 
curcumin (CCM) and the release profiles were studied in the absent and presence of GSH. 
The disulfide bond in the 4,4′‐DTBA was efficiently cleaved by GSH, leading to the MOF 
framework's dissociation and the subsequent CCM release. In vitro and in vivo 
experiments indicated the superior anticancer efficacy of CCM@MOF-Zr(DTBA) over 
that of free CCM.  
By exploiting the presence of specific ions (e.g., phosphate anions) as stimulus to trigger 
the drug release, an interesting MOF-based DDS were developed by Chen et al. for the 
oral delivery of insulin, which is the most important protein drug for the treatment of type 
I diabetes [92]. Advancements in developing an oral insulin delivery agent have been 
hindered by challenges arising from the instability of insulin in the stomach. However, 
when using Zr-MOF (NU-1000) as a carrier for oral delivery of insulin, these acid-stable 
MOF has a two-fold function: i) maintain the integrity of insulin in the stomach acid 
environment, and ii) exclude pepsin (digestive enzyme) from getting access to the insulin, 
and thus limiting its proteolysis. However, under simulated physiological conditions (e.g., 
in the bloodstream), the insulin is released from NU-1000 owing to the disassembly of 
this MOF in the presence of phosphate ions, which competitively binds to Zr clusters. 
This example shows clearly the dual function of the MOF which not only carries the drug 
to target site but also protects it from decomposing during transportation. 
Adenosine triphosphate (ATP) is a very important complex organic chemical that 
provides energy to drive many processes in living cells. ATP is present in low 
concentrations (<0.4 mM) in the extracellular environment but concentrated in the cytosol 
(1–10 mM), and it is also overexpressed in cancer cells. Thus, ATP can be used as a 
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trigger for the controlled release of anticancer drugs or other functional cargoes such as 
proteins [93-95]. By this approach, Yang et al. developed very recently an ATP-
responsive ZIF-90 platform for the delivery of CRISPR/Cas9 (i.e. cytosolic protein and 
clustered regularly interspaced short palindromic repeats-associated protein 9), which is 
a very promising genomic editing tool (cf. Fig. 2a) [75]. The protein CRISPR/Cas9 could 
be successfully encapsulated into ZIF-90 without affecting to its intrinsic function. High 
concentration of intracellular ATP promoted the disassembly of ZIF-90/protein due to the 
competitive coordination between the metal node of ZIF-90 (Zn+2) and ATP, thus 
releasing the CRISPR/Ca9. The feasibility of this DDS was demonstrated by knocking 
out the expression of the green fluorescent protein in HeLa cells as consequence of the 
effective release of CRISPR/Cas9. Another demonstration was performing by 
encapsulating the cytotoxic RNase A into ZIF-90 and observing the inhibition of cancer 
cell growth. It is interesting to note that this work demonstrates that MOFs are able not 
only of carrying proteins into cells, but also transporting them to the cytosol (i.e., efficient 
endosomal escape) in response to the intracellular environment. 
The major disadvantage of these intrinsic stimuli-responsive systems is the low 
flexibility, and low level of control. Temporal control of the drug release is not possible, 
as this will occur as soon as the DDS reaches a site containing the specific stimulus 
component. In addition, some of these DDS lack of selectivity, and thus, may respond to 
other non-intended stimulus leading to the drug release in a non-desired location. On the 
other hand, in case that the release mechanism is the degradation/disassembly of the 
MOF, the kinetic of the drug release is dictated by the intrinsic instability of the MOF 
under the specific conditions. As demonstrated in the discussed works, the degradation 
rate can be tuned by playing with the nature and size of the MOF, and therefore the drug 
release can vary from hours to days, but an initial delay is not possible. Importantly, the 
post-synthetic modification of the MOF surface with polymers is an alternative way of 
achieving prolonged release times. In this manner, MIL-101-Fe MOF particles loaded 
with ibuprofen were coated with polyethyleneglycol (PEG) layer for extending the drug 
release time by controlling the fast pH-mediated MOF degradation in biological buffers 
[96]. Moreover, the fast degradation of this kind of MOFs in the presence of phosphate 
ions (in PBS buffer) was overcome because of the phosphate anions had to diffuse 




It is important to highlight that the drug release mechanism involved in the above 
presented examples is the disassembly or degradation of the MOF triggered by a specific 
stimulus once the DDS reaches the desired location. However, the drug release can also 
occur through a gate mode mechanism, where “gates” are modified with capping units 
(e.g., molecular or supramolecular switches or chemically modified MOF) as a “lock” to 
regulate the flow of the drug molecules, and thus control the drug release. An interesting 
approach for the design of MOF-based DDS based on this release mechanism is the 
preparation of MOFs loaded with a drug, and further functionalized with stimuli‐
responsive DNA capping units. These DNA caps could be unlocked by different triggers, 
such as pH [97], cleavage of the caps by the metal-ion-driven activation of a DNAzyme 
[97], or formation of ATP–aptamer complexes [98]. These DNA-gated nMOFs were 
prepared by covalent attachment of the nucleic acids to the nMOF surface via “click-
chemistry”. In the presence of the appropriate trigger (pH = 5, metal ions, or ATP) 
depending on each DDS example, the nMOFs were unlocked, leading to the release of 
the loaded drug. All these DDS revealed selective cytotoxicity toward MDA-MB-231 
breast cancer cells as compared to MCF‐10A normal epithelial breast cells, owing to the 
successful release of DOX. 
Exogenous stimuli. Light and magnetic field are the most commonly used and promising 
exogenous stimuli due to their particular properties, and for that reason the selected 
examples discussed in the following are light- or magnetic-responsive MOF-based DDS. 
Importantly, exogenous stimuli allow more accurate control over the DDS than 
endogenous ones, particularly with regard to temporal and dosage control. That is the 
reason why they have emerged as the third generation of MOF-based DDS. On the one 
hand, the amount of drug delivered can sometimes be controlled by the intensity/duration 
of the stimulus. On the other hand, the possibility of stopping the drug release by 
switching off the stimulus, and activating later the release again (i.e., operating in on/off 
cycles) is very appealing. Furthermore, these stimuli are independent of the biological 
environment conditions, enabling a precise and explicit triggering of the drug release and 
avoiding individual variability. These are the clear advantages of exogeneous stimuli-
responsive DDS over the endogenous ones. However, they lack the autonomy associated 
with endogenous stimuli. 
Light as an exogenous stimulus for controlled drug delivery is advantageous for a number 
of reasons including its non-invasive nature, high spatial resolution and temporal control, 
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and convenience and ease of use. Additionally, a broad range of parameters (wavelength, 
light intensity, duration of exposure, and beam diameter) can be adjusted to modulate 
release profiles. In particular, near-infrared (NIR) light (650  900 nm) is preferred 
because it can penetrate deeper than visible light. Moreover, NIR light is innocuous, that 
is, it does not cause any significant damage in the area of its application. Therefore, NIR 
light has been successfully used for triggering drug release on demand at well delimited 
sites of the body. There are five types of mechanisms for light-triggered drug delivery, 
but they all have in common that materials absorb electromagnetic radiation and convert 
it to various forms of energy, which is ultimately responsible for the release [99]. These 
different mechanisms are: (1) photochemically triggered, where the absorbed light energy 
is sufficient to break covalent bonds directly or by a photochemical reaction; (2) 
photoisomerization, where the excess energy causes structural changes; (3) photothermal, 
where the absorbed photon energy is dissipated via vibrational motion and thus generating 
heat; (4) two-photon absorption, where two photon are adsorbed and the resulting energy 
activates a photosensitive material; and (5) photon upconversion, where the absorbed NIR 
light is converted into high energy UV/Visible photons to activate a photosensitive 
material. Depending on the mechanism involved, some light‐responsive DDS are of a 
single use (i.e. the light triggers an irreversible structural change that provokes the 
delivery of the entire dose) while others are able to undergo reversible changes when 
on/off cycles are applied, releasing then the drug in a pulsatile manner.  
As an example of the single-use type, Stefaniak et al. developed a light-responsive UiO-
type MOF incorporating photoisomerizable azobenzenedicarboxylate (AZB) linkers 
[100]. Such nanosized UiO-AZB degrades upon irradiation with UV light due to the 
photoisomerization of the AZB linker, while no degradation is observed in the dark over 
time [101]. 5-fluorouracil (5-Fu) was loaded into the MOF, and an aminated polyethylene 
glycol (PEG-NH2) coating was post-synthetically attached to the MOF surface to 
increase the aqueous stability and biocompatibility. The irradiation with UV light 
triggered the degradation of the PEGNH2@5-FuUiO-AZB, leading to the 5-Fu release 
and the subsequent concentration-dependent cell death. Based on a similar release 
mechanism, i.e., photoisomerization, but without causing degradation of the MOF, Wang 
et al. reported a light-responsive DDS consisted of a UiO-68 MOF modified first with 
azobenzene stalks on the surface, and capped then with β-cyclodextrin (β-CD) onto the 
azobenzene by host-guest interactions [102]. UV light irradiation induced the 
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isomerization of azobenzene from trans to cis, and this structural change promoted the 
dethreading of the gating β-CD. This in turn exposed MOF pores to the solvent, 
facilitating thus the cargo release (rhodamine B used as model) from the MOF. A clear 
drawback of these two DDS is that they require the use of UV light, which is not 
compatible with living cells, and thus the application under real conditions for 
intracellular drug release is hampered. 
To overcome this issues, NIR light-responsive nanosized DDS are nowadays preferred 
and have a brighter future [103-105]. Most of them are designed as core-shell 
nanoparticle@MOF structures and the drug release mechanism relies on photothermal 
effect. In this direction, a plasmonic core–shell nanocomposite comprising gold nanostars 
coated with ZIF-8 and stabilized with an amphiphilic polymer was developed for light-
triggered release of encapsulated cargo inside cells [105]. The post-synthetic 
functionalization with an amphiphilic polymer prevented ZIF‐8 degradation and cargo 
(bisbenzimide as model) leaking in aqueous media and inside living cells (cf. Fig. 2b). 
The release mechanism involved here was photothermal effect; that is, NIR light 
irradiation coupled to the plasmonic absorption of the core gold nanostars created local 
temperature gradients and thus, cargo thermodiffusion. The successful release of the 
cargo inside cells was easily confirmed by visualizing the location of the fluorescence 
from the cargo: first as blue fluorescent dots at the endosomes/lysosomes before release, 
and bright nuclei-staining after NIR irradiation as consequence of the cargo release. 
Magnetic field represents also an attractive tool for a wide variety of uses in biomedical 
applications, such as magnetic separation, magnetic targeting, magnetic resonance 
imaging (MRI), and magnetic hyperthermia [106-108]. The major advantage of using 
magnetic field as external stimulus is that has a dual function in DDS: (1) allow the 
directivity toward the targeting area (i.e., magnetically guided DDS), which is a unique 
strategy to concentrate the DDS in tumor sites leading to improved therapeutic efficacy;  
and (2) provide a controlled release of drugs through the conversion of magnetic energy 
into thermal energy. Generally, magnetic field-responsive MOF-based DDS are core-
shell systems containing magnetite (Fe3O4) or maghemite (Fe2O3) nanoparticles in the 
core [109-111]. These nanoparticles with an average diameter of about 20 nm exhibit 
superparamagnetic property and possess considerable saturation magnetization to be 
directed to specific parts of the body using a weak external magnetic field [112]. 
Furthermore, these magnetic nanoparticles can generate heat under an alternate current 
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(AC) magnetic field due to the relaxation of its magnetic moment. Interestingly, by 
modulating the strength of the magnetic field and/or size of the nanoparticles the amount 
of heat generated can be controlled. For these reasons, the employment of magnetic 
nanoparticles to design magnetic field-responsive MOF-based composites with high 
relaxivity, large drug payload and good biocompatibility is appealing. More importantly 
and to exploit the full potential of magnetic MOFs, they are nowadays being widely 
studied as theranostic systems for MRI‐guided therapy as it will be discussed in a next 
section with some recent examples. 
Despite the clear advantages of external stimuli-responsive DDS, they also have its 
drawbacks. For instance, the light-responsive modality suffers from shallow penetration, 
and the magnetic-responsive modality needs a large amount of sample to work. Therefore, 
multiple stimuli-responsive modality is developing to overcome these limitations. 
Multiple stimuli‐responsive MOF-based DDS 
The individual drawbacks of each stimulus, together with the complexity of the human 
body environment make that the delivery of drugs or functional cargoes in a precise and 
accurate manner is not a straightforward task. These issues may be overcome by 
designing DDS responsive to multiple triggers rather than a single stimulus. Thus, 
multiple stimuli‐responsive MOF-based DDS are being developing to improve the overall 
performance of DDS, and consequently the therapeutic efficacy. Table 1 summarizes the 
representative examples discussed below. 
Among the developed multiple-stimuli MOF-based DDS, increasing attention is given 
recently to the combination of MOFs with supramolecular chemistry for getting a better 
control of the drug release by exploiting the unique properties of supramolecular materials 
such as their special structure, facile functionalization, and desirable host–guest 
performance [102, 113, 114]. MOF surfaces have been successfully functionalized with 
supramolecular host molecules such as pillararenes and cyclodextrins [115-120]. These 
macrocycles can act as supramolecular gates or nanovalves, allowing the formation of 
host-guest complexes in a manner that is sensitive to, or can be governed by, either 
externally applied triggers, disease-specific analytes, or the presence of a competing 
guest. Recently, a triply‐responsive (pH, Ca2+, and temperature) DDS based on Zr-MOFs 
functionalized with carboxylatopillar[5]arenes CP[5]A as supramolecular switches was 
developed by Tan et al. [97]. Positively charged quaternary ammonium salt stalks were 
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tethered on UiO‐66‐NH2 via post‐synthetic modification, and then negatively charged 
CP[5]A was encircled on the stalks sitting on the surface of the MOF through host–guest 
complexation (cf. Fig. 2c). CP[5]A act as gating nanovalves to control the release of the 
therapeutic molecule 5‐Fu previously loaded within the pores of Zr‐MOF. Low pH, 
increasing temperature, and competitive binding agents could weaken the supramolecular 
host-guest interactions between the MOF scaffold and the CP[5]A gating nanovalves, 
leading thus to the release of the drug. Controlled release experiments revealed that lower 
pH and higher concentration of Ca2+ in osteoclasts and tumor cells could stimulate the 
release of the drug via pH‐responsiveness and Ca2+‐competitive responsiveness, having 
thus potential application in bone regeneration and bone cancer therapy. Moreover, high 
temperatures could also weaken host–guest interactions to prompt gradually drug release. 
Within multiple stimuli-responsive DDS, self‐regulated systems are a particularly 
interesting type of MOF-based DDS. They can detect certain changes in biological 
variables (e.g., pH or concentration of some substances) by activating or modulating the 
response, that is, by switching drug release on and off or automatically adjusting the 
release rate. Recently, a smart sense-and-treat MOF carrier was developed by encapsulating 
both insulin and glucose oxidase into ZIF-8 nanoparticles [121]. Insulin is commonly used in 
the treatment of type I diabetes because it can lower the blood glucose level; however, insulin 
may lead to hypoglycemia when using not properly. To overcome this issue, glucose oxidase 
(GOx) was in this system used as a sensor of glucose, being the insulin release controlled by 
the concentration of glucose. In the presence of high levels of glucose, GOx converted glucose 
to gluconic acid and lower the pH of the local microenvironment (cf. Fig. 2d). Due to the pH-
sensitivity of the ZIF-8, the low pH led to the degradation of ZIF-8, releasing thus the loaded 
insulin to balance the blood glucose level. On the other hand, the lower blood glucose level 
balanced by insulin could also balance the pH of the local microenvironment, thus regulating 
the release of insulin. Therefore, this smart glucose-responsive insulin release displayed the 





Fig. 2 Selected examples of stimuli-responsive MOF-based DDS. (a) Scheme of ATP-
triggered cytosolic protein (CRISPR/Cas9) release from ZIF-90 nanoparticle and genome 
editing. Adapted with permission from [95]. Copyright 2019, American Chemical Society. 
(b) Au nanostar/ZIF-8 nanocomposite (NC) for light-triggered released of encapsulated cargo 
inside cells. Confocal microscopy images of HeLa cells incubated with the nanocomposite 
loaded with the Hoechst (cargo molecule) before and after near-IR irradiation are shown. Blue 
and orange color represent Hoechst and cell membrane staining (CellMaskTM Deep Red), 
respectively. Adapted with permission from [105]. Copyright 2018, John Wiley & Sons, Inc. 
(c) Triply‐responsive (pH, Ca+2, and temperature) Zr-MOF, which is modified with positively 
charged A stalks encircled by carboxylatopillar[5]arene (CP[5]A) rings on the surfaces, for 
on-command release of drug (5-Fu). Adapted with permission from [117]. Copyright 2016, 
Royal Society of Chemistry. (d) Scheme of the insulin/GOx-loaded ZIF-8 nMOFs and the pH-
induced degradation of the nMOFs through the GOx-catalyzed oxidation of glucose. Adapted 
with permission from [121]. Copyright 2018, American Chemical Society. 
Multifunctional MOF-based theranostic platforms 
Over the years, there has been a gradual paradigm shift from traditional medicine, which 
has been based on identifying therapies which target an entire population, to the concept 
of "personalized medicine" [122]. This means a shift from the mindset of ‘one-drug-fits-
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all’ to ‘the right drug for the right patient at the right dose and time’ [123]. This latter 
approach relies on tailoring of treatment to the unique molecular or genetic mapping of 
individual patients and how these unique features contribute to the occurrence of certain 
disease pattern and progression [124, 125]. In line with this change, the drug delivery 
field is currently evolving towards the development of theranostic nanosystems, which 
are able to combine therapy and diagnosis in one integrated system [126-128]. Due to the 
rapid advances in the design of customized MOFs and its tremendous potential of being 
endowed with multifunctionality, MOF-based theranostic platforms are developing 
quickly and will surely play a key role in the development of personalized medicine [45, 
52]. The integration of favourable biocompatibility, high drug loading ability, active 
tumor-targeting ability, and imaging-guided smart drug delivery is the key to taking full 
advantage of nanoscale MOFs for tumor theranostics. These platforms could allow 
monitoring the drug release, its biodistribution and accumulation at the target site, dose 
adjustment to individual patients and eventually, monitoring the course of a disease. 
Herewith, the potential of MOFs as theranostic platforms is highlighted by means of some 
selected examples, summarized in Table 1. 
The rational structural design of nMOFs for imaging-guided therapy will be different 
depending on the proper imaging modality for the intended application. For example, the 
incorporation of paramagnetic metal ions (such as Fe2+ [52], Gd3+ [54], and Mn2+ [129]) 
in the nMOF or the use of core-shell magnetic nanoparticle@MOF [53, 130] have been 
proposed as imaging contrast agents for magnetic resonance imaging (MRI). Otherwise, 
using luminescent building blocks for the construction of nMOF [131], encapsulating 
fluorescent organic dyes into the nMOF [132], or designing core-shell luminescent 
nanoparticle@MOF [133] allow for optical imaging modality.  
Zhang et al. have recently developed an effective theranostic system based on a Mn-
porphyrin nMOF for MR imaging-guided controllable NO release and photothermal 
synergetic therapy under single NIR irradiation [129]. nMOFs were prepared with 
biocompatible Zr+4 ions and Mn-porphyrin as a bridging ligand, and further 
functionalized with S-Nitrosothiol (SNO) on the surface for heat-sensitive NO 
generation. The insertion of paramagnetic Mn ions into porphyrin rings provides strong 
T1-weighted MR contrast capacity and high photothermal conversion for efficient 
photothermal therapy (PTT) without increasing their complexity. Irradiation with NIR 
light triggered the controllable NO release for NO therapy and PTT simultaneously with 
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one-step operation. Irradiation achieves photothermal conversion for PTT and 
controllable NO release for NO therapy simultaneously. The system was validated with 
cells and mice as models, confirming the efficiency of in vitro and in vivo NO and 
photothermal synergistic therapy. However, NO treatment is still not well understood, 
and thus the biological effects of NO therapy should be evaluated with further research. 
By taking advantage of nanoparticle@MOF (NP@MOF) core‐shell structures, which 
encompass the benefits of the porous structure of the NMOF and the unique properties of 
NPs, Deng et al. developed a core-shell NP@MOF platform for fluorescent imaging-
guided therapy, allowing simultaneous targeted drug delivery and cell imaging of cancer 
cells [134]. This theranostic platform consisted of up-conversion luminescent 
NaYF4:Yb
3+/Er3+ nanoparticle (UCNP) core, which could emit strong green emission 
under 980 nm laser, and mesoporous MIL‐100(Fe) as shell for loading the anticancer drug 
DOX. Moreover, the AS1411 aptamer was covalently conjugated to the MOF surface for 
targeting cancer cells and enhancing intracellular uptake, since it can bind to nucleolin (a 
receptor for AS1411 and overexpressed on the plasma membrane of tumor cells). The 
UCNPs@MOF-DOX-AS1411 exhibited a pH‐sensitive release of the DOX that lasted as 
long as 35 days. These nanocomposites could specifically recognize cancer cells, go 
across the cell membrane by receptor-mediated endocytosis, exhibit up-conversion 
fluorescence imaging under 980 nm laser, and ultimately release DOX leading to high 
cytotoxicity to MCF‐7 cells. Thus, this platform showed great promising for simultaneous 
targeted labeling and therapy of cancer cells.  
Exploiting not only the benefits of NP@MOF structures but also the potential of 
supramolecular chemistry discussed above, Wu et al. reported the construction of a 
theranostic core-shell nanoplatform comprising of Fe3O4 magnetic nanoparticles as core, 
UiO-66 MOF as shell allowing a high loading of the drug (5-Fu), and CP[6]A-based 
pseudorotaxanes (WP6) anchored on the surface as the gatekeepers [135]. Remarkably 
this system, 5‐Fu‐loaded Fe3O4@UiO‐66@WP6, integrated multi-functions including 
tumor microenvironment-responsive drug release (triple responsiveness towards pH, 
temperature and competitive binding agents), effective chemotherapy, sustained release 
ascribed to the tight host-guest interactions, and superior abilities of magnetic resonance 
imaging (MRI), which eventually resulted in an enhanced in vitro therapeutic effect. 
Importantly, they also demonstrated the relevance of the proper selection of the 
macrocyclic molecules as gatekeepers or nanovalves in the precise control of the drug 
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release. Comparing with the carboxylatopillar[5]arene (WP5)‐based nanovalve system 
with less gate tightness as a control, the WP6‐based one exhibited a prolonged drug 
release owing to the stronger binding capacity of WP6 toward the stalks on MOF surface. 
Although optical and magnetic resonance imaging are the imaging modalities most 
commonly used there are a few examples of theranostic MOF-based platform based on 
other imaging techniques such as photoacoustic (PA) imaging, which is a noninvasive 
imaging modality that detects the pressure wave caused by the photoacoustic effect. Wang 
et al. combined the merits of nMOF and polydopamine (PDA) to design a multifunctional 
nanoplatform for photoacoustic imaging (PAI)-guided chemo-/photothermal 
combinational tumor therapy [136]. MIL-100 MOF was utilized to load curcumin as 
chemotherapeutic drug and was further coated with polydopamine-modified hyaluronic 
acid (HA-PDA) with the aim of improving the stability in the systemic circulation in vivo 
of nMOFs, as well as providing tumor-targeting ability. Moreover, PDA was selected due 
to the already proven high photothermal conversion efficiency and also its potential as 
PA contrast agent. The good efficiency of the curcumin-loaded MIL-100@HA-PDA 
nanoplatform was demonstrated in vitro and in vivo. After being intravenously injected 
into xenograft HeLa tumor-bearing mice, the nanoplatform was preferably accumulated 
at the tumor site and achieved photoacoustic imaging-guided chemo-/photothermal tumor 
therapy, generating nearly complete tumor ablation. 
Taking into account that each imaging modality has its advantages and limitations (e.g., 
high sensitivity but poor resolution and shallow tissue penetration in the case of optical 
imaging, whereas MRI possesses high resolution and good soft tissue contrast but low 
sensitivity) [137], the development of nMOFs endowed with dual MR/optical imaging 
potential is desirable for the ultimate goal of in vivo application [132, 138-140]. Going a 
step further, the possibility of integrating three imaging modalities (fluorescence, MR, 
and PA) together with photothermal therapy (PTT) of cancer under NIR laser irradiation 
into a single MOF-based platform has been recently demonstrated [132]. Cai et al. 
developed a multifunctional ICG-engineered MOF coated with hyaluronic acid (HA) as 
nanotheranostic agent for anticancer treatment (cf. Fig. 3). The incorporation of 
photoresponsive indocyanine green (ICG; the only NIR organic dye for clinical 
applications approved by the FDA) into the MOF MIL-100(Fe) enhanced ICG’s tumor 
accumulation and endowed the MOF with strong NIR fluorescence, which allowed not 
only for optical imaging but also for PA imaging. Fe3+ ions in the MOF NPs were used 
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for T2-weighted MRI, and the functionalization of the MOF surface with HA mediated 
the targeting recognition of CD44 overexpressing cancer cells. Importantly, this 
MOF@HA@ICG nanoplatform exhibited good NIR absorbance, low cytotoxicity, great 
cellular uptake in CD44-positive MCF-7 cancer cells and tumor accumulation in 
xenograft tumors, and good in vitro and in vivo capabilities in fluorescence imaging, PAI, 
T2-weighted MRI, and PTT treatment under NIR irradiation. Significant MCF-7 cell 
death in vitro and efficient suppression of MCF-7 tumor growth in vivo were observed. 
Therefore, this theranostic MOF@HA@ICG nanoplatform is very promising for 
imaging-guided PTT cancer therapy of solid tumors, contributing significantly toward the 
clinical translation of MOF-based hybrid nanocomposites. 
 
Fig. 3 (a) Schematic representation of the preparation of the theranostic MIL-100(Fe) 
MOF@HA@ICG nanoplatform and its multimodal imaging-guided PTT performance. 
(b) FL images of MCF-7 tumor-bearing mice injected with free ICG, MOF@ICG, or 
MOF@HA@ICG solutions (each with 170 μg/mL of ICG). (c) in vivo PA images. (d) 
T2-weighted MR images with MOF@HA@ICG treatment. The tumors are highlighted 


















Table 1. Representative examples of MOF-based DDS including the relevant features. 
MOF Components Drug 
Loading 
(wt%) 
DDS type Stimuli Capability in vitro/in vivo studies Ref. 













pH chemotherapy In vitro: MCF‐7 [85] 
BSA@ZIF-8 
BSA NPs 




pH chemotherapy In vitro: MCF‐7 [87] 






In vitro: HeLa, MDA-
MB-231 
In vivo: tumor-bearing 
BALB/c nude mice 
[91] 





chemotherapy  [92] 
ZIF-90 Zn+2, ICA CRISPR/Cas9  
Single-
stimulus  









































ZrCl4, AZB, PEG 5-fluorouracil 15 
Single-
stimulus  
Light chemotherapy  [100] 
β‐CD‐capped UiO‐
68‐azo 
ZrCl4, azo, β-CD Rhodamine B  
Single-
stimulus  
Light chemotherapy  [102] 
PMA‐capped ZIF-
8@AuNS 
Zn+2, MeImz, PMA Hoechst 5 
Single-
stimulus  
Light chemotherapy In vitro: HeLa [105] 
CP[5]A‐capped 
UiO‐66‐NH2 
ZrCl4, 1,4‐BDC-NH2, CP[5]A, 






chemotherapy In vitro: HEK293 [117] 
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sensing, therapy In vitro: MCF‐10A [121] 









sensing, therapy In vitro: MCF‐10A [121] 








In vitro: MCF‐7 [129] 
UCNP@MIL‐
100(Fe)-AS1411 


























In vitro: HUVEC, HeLa [135] 
MIL‐100(Fe)-HA-
PDA  












In vitro: HeLa, A549, 
CHO, MRC-5 
In vivo: tumor-bearing 









imaging, PAI,  
MRI 
In vitro: MCF‐7, NIH-3T3 
In vivo: tumor-bearing 
Balb/c nude mice 
[132] 
abbreviations: MeImz = 2-methylimidazole; PAA = poly(acrylic acid); BSA = bovine serum albumin; DTBA = 4,4′‐dithiobisbenzoic acid (4,4′‐DTBA); GSH = 
glutathione; TBAPy = tetratopic 1,3,6,8-tetrakis(p-benzoate)pyrene: ICA = imidazolate-2-carboxyaldehyde; ATP = adenosine triphosphate; TPDC = terphenyl-4,4′-
dicarboxylate; AZB = azobenzenedicarboxylate; PEG = polyethylene glycol; azo = 2′‐p‐tolyldiazenyl‐1,1′:4,4′‐terphenyl‐4,4′′‐dicarboxylic acid; β-CD = β-
cyclodextrin; AuNS = gold nanostar; PMA = poly[isobutylene‐alt‐maleic anhydride]‐graft‐dodecyl; CP[5]A = carboxylatopillar[5]arene; 1,4-BDC-NH2 = 2-
amino-1,4-benzenedicarboxylic acid; GOx = glucose oxidase; VEGF aptamer = antivascular endothelial growth factor aptamer; MRI = magnetic resonance 
imaging; TCPP = tetrakis(4-carboxyphenyl)porphyrin; PTT = photothermal therapy; PVP = polyvinylpyrrolidone; WP6 = carboxylatopillar[6]arene; BTC = 




Challenges and perspectives 
Despite the rapid and incredible progress made in recent years, further research studies are 
required for fully understand the interactions and mechanism involved in those MOF-based 
nanoplatforms, and thus be able to exploit the entire potential of these materials in drug 
delivery, and specially in theranostics. Researchers will have to address the following issues 
and challenges before the translation of these MOF-based nanoplatforms into the clinical 
practice in future. 
i) Refinement of the MOF design and synthetic methods. More precise optimization of the 
MOF-based material in terms of size, morphology, surface properties, and incorporation of 
additional functionalities should be made in order to ensure the prolonged blood circulation, 
stability under physiological condition at least until reaching the target site, controllable cargos 
release, enhanced cell uptake, and selective targeting after systemic in vivo administration. In 
spite of the great advances in engineering the MOF surface (e.g, silica and polymer coatings), 
many MOF types have still limited stability in aqueous and buffer solutions which hampers 
their application as DDS. Importantly, the administration route of the DSS, which will depend 
on the intended application, must be taken into account for the proper selection of the desirable 
physicochemical properties, and thus design the MOF accordingly. For example, parenteral 
route requires particles with size less than 200 nm to freely circulate in smallest capillaries [43]. 
Regarding the MOF preparation, the synthesis of MOFs is largely performed under 
solvothermal conditions in high boiling point, polar solvents such as dimethylformamide and 
diethylformamide [141]. Faced with growing environmental issues and the increasing demand 
for sustainable products and processes, the development of greener methods (i.e., reducing 
waste production, minimizing the use of organic solvents, reducing the use of hazardous 
reagents or by-products, maximizing yields, etc.) is of utmost importance [142-144]; however 
this is a major challenge for synthetic material chemists. Nowadays, there are significant 
research efforts dedicated to finding suitable replacement solvents for the synthesis of MOFs 
[145-147]. The fact that some MOFs are already commercially available has been probably a 
driving force for the emerging interest in up‐scaling of MOFs synthesis and the adjustment of 
synthetic conditions towards sustainable industrial processes [144]. On the other hand, the 
formulation of the MOFs in a suitable form (patches, pellets, tablets, creams, etc) is also an 
important aspect, not studied much to date, that will depend strongly on the administration route 
(oral, intravenous, intranasal, cutaneous, etc.) [42, 43, 148, 149]. More research in this direction 
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is needed for the practical application of MOFs.ii) Simplicity and reproducibility of preparation. 
There is a generalized trend of designing increasingly sophisticated and complex DDS, having 
long synthetic procedures and sometimes high cost preparation because of the complicated 
organic ligands involved. On the one hand, the complexity of the preparation procedure may 
lead to lack of reproducibility from batch to batch, which ultimately results in differences in the 
DDS performance in vitro and in vivo. On the other hand, the high cost of complicated organic 
ligands will finally restrict the practical application of these DDS. Therefore, the golden rule to 
follow should be "the simpler, the better”, as long as the DDS meets the essential requirements 
for the intended application. 
iii) Biosafety. This is a major concern for clinical application of nanomedicine; therefore, more 
systematic in vitro and in vivo studies for investigating the toxicity of MOF-based 
nanomaterials are mandatory. Currently, only very few studies on the in vivo toxicity of MOFs 
have been performed [150-153]. Careful selection of the inorganic and organic building blocks 
for constructing the MOF is the first step in ensuring biosafety. They must be nontoxic or low-
toxic to ensure the safety of decomposition products in the body and further to process through 
the body’s metabolic system. The controlled biodegradability of the MOF, that is its 
decomposition at a desired region, is recommended to avoid endogenous accumulation. 
Furthermore, the “ADME” (“absorption - distribution - metabolism - excretion”) mechanism 
of MOF-based DDS need to be fully evaluated after in vivo administration. It is worth 
mentioning that small animal models commonly used for in vivo studies have not been a good 
predictor of the drug efficacy and DDS performance in humans. Therefore, innovative in vitro 
models should be developed to accurately predict the in vivo pharmacokinetic profiles in 
humans. This will mean a huge step towards the successful clinical translation of these DDS. 
iv) Regulatory issues. Ultimately, any MOFs destined for the clinic must first meet stringent 
safety and efficacy standards set by regulatory agencies, such as the Food and Drug 
Administration (FDA) in United States, before being approved for use on patients. However, 
conducting clinical trials is expensive, and pharmaceutical companies drug manufacturers 
usually prefer spending their legal and lobbying resources on modifications of existing 
technology (already earned FDA approval) instead of novel therapies. Therefore, a change of 
mind set is of utmost importance for the future of MOFs, and whichever other nanomaterial, in 
biomedicine. Currently there is only one MOF-based system for the treatment of cancer under 
a phase 1 clinical trial (NCT03444714). This MOF systems, developed by Lin’s group at the 
University of Chicago and further exploited by his company RiMO Therapeutics, enable 
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synergistic radiotherapy-radiodynamic therapy and immunotherapy using extremely low doses 
of X-rays [154]. On the other hand, Morris’s group is embedding nitric oxide (NO)-filled MOFs 
in bandages to promote wound healing and coating stents and catheters with the material to 
prevent blood clots and reduce infection risk [154]. His spin-off company (MOFgen) is 
currently raising funds to registering NO-filled MOFs for use in medical devices. 
These weakness and open issues point out the opportunities and challenges for the future 
perspectives in the progress of MOF-based materials as DDS and theranostic platforms. By 
resolving these issues, researchers will yield significant advances paving the way towards 
personalized medicine. 
Conclusions 
The development of MOF-based nanomaterials as drug nanocarriers and theranostic systems 
has attracted much attention from the scientific community in the last decade (20082018). 
This is mainly due to their unique properties such as large surface area, high drug loading 
capacity, tailorable composition and structure, versatile functionality, and biodegradability, 
which are far superior to those of any other nanocarrier material. The examples discussed along 
the review are illustrative of the continually expanding interest and bright future for MOFs in 
this field. However, more effort should be devoted to the development of MOF-based DDS 
with better therapeutic efficacy not only for cancer but also for other diseases. Most importantly, 
more systematic investigations on their toxicity after long-term use and in vivo studies with 
these systems should be conducted to evaluate possible side effects before their clinical 
translation. 
Going forward, research should focus on the development of multimodal MOF‐based 
theranostic nanoplatforms combined with different mechanisms to benefit from the full 
potential of this relatively new class of porous materials. Although theranostic MOFs for 
clinical applications are still a long‐standing challenge, great achievements have been made in 
such a short period of time.  
Finally, it must keep in mind that developing a MOF-based DDS or theranostic MOF-based 
platform from the structural design to the preclinical evaluation is an interdisciplinary task, and 
thus the involvement of chemists, pharmacologists and clinicians at an early stage would be the 
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